A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure
In this randomized, double-blind, placebo-controlled, multicentre, parallel, 8-week study, the efficacy of a daily dose of 1200 mg of protein hydrolysate from Coldwater Shrimp (Pandalus borealis) on ambulatory and office blood pressure was investigated in 144 free-living adults with mild to moderate...
Published in: | International Journal of Hypertension |
---|---|
Main Authors: | , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Wiley
2019
|
Subjects: | |
Online Access: | https://doi.org/10.1155/2019/2345042 https://doaj.org/article/dadb2dc34ef540a0b7c4790cb0be449a |
id |
ftdoajarticles:oai:doaj.org/article:dadb2dc34ef540a0b7c4790cb0be449a |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:dadb2dc34ef540a0b7c4790cb0be449a 2024-09-15T18:29:08+00:00 A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure Kathy Musa-Veloso Lina Paulionis Tetyana Pelipyagina Mal Evans 2019-01-01T00:00:00Z https://doi.org/10.1155/2019/2345042 https://doaj.org/article/dadb2dc34ef540a0b7c4790cb0be449a EN eng Wiley http://dx.doi.org/10.1155/2019/2345042 https://doaj.org/toc/2090-0384 https://doaj.org/toc/2090-0392 2090-0384 2090-0392 doi:10.1155/2019/2345042 https://doaj.org/article/dadb2dc34ef540a0b7c4790cb0be449a International Journal of Hypertension, Vol 2019 (2019) Diseases of the circulatory (Cardiovascular) system RC666-701 article 2019 ftdoajarticles https://doi.org/10.1155/2019/2345042 2024-08-05T17:48:34Z In this randomized, double-blind, placebo-controlled, multicentre, parallel, 8-week study, the efficacy of a daily dose of 1200 mg of protein hydrolysate from Coldwater Shrimp (Pandalus borealis) on ambulatory and office blood pressure was investigated in 144 free-living adults with mild to moderate hypertension. The primary outcomes of the study were daytime ambulatory systolic blood pressure and office blood pressure. During the 8-week intervention period and in the intention-to-treat analysis (n=144), there were significant reductions in the group consuming the shrimp-derived protein hydrolysate relative to the placebo group in daytime ambulatory systolic blood pressure at 4 weeks (p=0.014) and at 8 weeks (p=0.002), and in office systolic blood pressure at 2 weeks (p=0.031) and 4 weeks (p=0.010), with a trend toward significance at 8 weeks (p=0.087). By 8 weeks, significant and favourable improvements in the group consuming the shrimp-derived protein hydrolysate relative to the placebo group were also observed for several secondary outcomes, including 24-hour ambulatory systolic and diastolic blood pressure, daytime ambulatory diastolic blood pressure, and daytime and 24-hour ambulatory mean arterial pressure. Also by Week 8, there was a statistically significant difference between groups in the distribution of subjects across National Institutes of Health-defined blood pressure categories (i.e., Normotensive, Prehypertensive, Stage 1 hypertension, and Stage 2 hypertension), with a more favourable distribution in the shrimp-derived protein hydrolysate group than in the placebo group (p=0.006). Based on exploratory analyses conducted only in participants in the shrimp-derived protein hydrolysate group, angiotensin II levels were significantly reduced relative to baseline. This study is registered at ClinicalTrials.gov NCT01974570. Article in Journal/Newspaper Pandalus borealis Directory of Open Access Journals: DOAJ Articles International Journal of Hypertension 2019 1 13 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Diseases of the circulatory (Cardiovascular) system RC666-701 |
spellingShingle |
Diseases of the circulatory (Cardiovascular) system RC666-701 Kathy Musa-Veloso Lina Paulionis Tetyana Pelipyagina Mal Evans A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure |
topic_facet |
Diseases of the circulatory (Cardiovascular) system RC666-701 |
description |
In this randomized, double-blind, placebo-controlled, multicentre, parallel, 8-week study, the efficacy of a daily dose of 1200 mg of protein hydrolysate from Coldwater Shrimp (Pandalus borealis) on ambulatory and office blood pressure was investigated in 144 free-living adults with mild to moderate hypertension. The primary outcomes of the study were daytime ambulatory systolic blood pressure and office blood pressure. During the 8-week intervention period and in the intention-to-treat analysis (n=144), there were significant reductions in the group consuming the shrimp-derived protein hydrolysate relative to the placebo group in daytime ambulatory systolic blood pressure at 4 weeks (p=0.014) and at 8 weeks (p=0.002), and in office systolic blood pressure at 2 weeks (p=0.031) and 4 weeks (p=0.010), with a trend toward significance at 8 weeks (p=0.087). By 8 weeks, significant and favourable improvements in the group consuming the shrimp-derived protein hydrolysate relative to the placebo group were also observed for several secondary outcomes, including 24-hour ambulatory systolic and diastolic blood pressure, daytime ambulatory diastolic blood pressure, and daytime and 24-hour ambulatory mean arterial pressure. Also by Week 8, there was a statistically significant difference between groups in the distribution of subjects across National Institutes of Health-defined blood pressure categories (i.e., Normotensive, Prehypertensive, Stage 1 hypertension, and Stage 2 hypertension), with a more favourable distribution in the shrimp-derived protein hydrolysate group than in the placebo group (p=0.006). Based on exploratory analyses conducted only in participants in the shrimp-derived protein hydrolysate group, angiotensin II levels were significantly reduced relative to baseline. This study is registered at ClinicalTrials.gov NCT01974570. |
format |
Article in Journal/Newspaper |
author |
Kathy Musa-Veloso Lina Paulionis Tetyana Pelipyagina Mal Evans |
author_facet |
Kathy Musa-Veloso Lina Paulionis Tetyana Pelipyagina Mal Evans |
author_sort |
Kathy Musa-Veloso |
title |
A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure |
title_short |
A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure |
title_full |
A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure |
title_fullStr |
A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure |
title_full_unstemmed |
A Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial of the Effects of a Shrimp Protein Hydrolysate on Blood Pressure |
title_sort |
randomized, double-blind, placebo-controlled, multicentre trial of the effects of a shrimp protein hydrolysate on blood pressure |
publisher |
Wiley |
publishDate |
2019 |
url |
https://doi.org/10.1155/2019/2345042 https://doaj.org/article/dadb2dc34ef540a0b7c4790cb0be449a |
genre |
Pandalus borealis |
genre_facet |
Pandalus borealis |
op_source |
International Journal of Hypertension, Vol 2019 (2019) |
op_relation |
http://dx.doi.org/10.1155/2019/2345042 https://doaj.org/toc/2090-0384 https://doaj.org/toc/2090-0392 2090-0384 2090-0392 doi:10.1155/2019/2345042 https://doaj.org/article/dadb2dc34ef540a0b7c4790cb0be449a |
op_doi |
https://doi.org/10.1155/2019/2345042 |
container_title |
International Journal of Hypertension |
container_volume |
2019 |
container_start_page |
1 |
op_container_end_page |
13 |
_version_ |
1810470546283954176 |